Comprehensive assessment of erenumab efficacy in participants with high‐frequency episodic migraine with at least one previously failed preventive treatment: The EMBRACE study
Headache: The Journal of Head and Face Pain · 2025
DOI: 10.1111/head.15071 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Headache: The Journal of Head and Face Pain, 2025. Verfasst von Gabriel Paiva da Silva Lima und 11 weiteren Autor:innen. Beteiligte Einrichtung: Amgen Inc., Thousand Oaks, California, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Antibodies, Monoclonal, Humanized, Calcitonin Gene-Related Peptide Receptor Antagonists, Outcome Assessment, Health Care. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Amgen Inc., Amgen.
Abstract (Originalsprache)
Objective
To evaluate the effect of erenumab treatment beyond monthly migraine days in patients with high‐frequency episodic migraine who did not respond to at least one previous migraine preventive treatment.
Background
Reduction in monthly migraine days has been the efficacy standard for migraine preventive treatments; however, it does not fully capture the holistic benefit of the therapy. Erenumab, a monoclonal antibody targeting the calcitonin gene–related peptide pathway, has demonstrated reduction in monthly migraine days and improvement in function in patients with episodic and chronic migraine.
Methods
In this phase 4, interventional, double‐blind, randomized, placebo‐controlled, multicenter, global study, treatment with erenumab was assessed over 4 months in adults with high‐frequency episodic migraine. The study was conducted at 61 sites located across North America and Europe between September 2020 and October 2023. Patients with ≥1 qualifying oral triptan‐treated migraine attack at baseline were randomized to receive erenumab 140 mg or placebo subcutaneously once monthly. The primary endpoint was change from baseline in mean monthly hours of at least moderate headache pain intensity over months 1, 2, and 3; secondary endpoints included change from baseline in mean monthly function, mean monthly duration of at least moderate pain intensity in migraine attacks, and mean monthly peak migraine pain intensity. Safety outcomes were also assessed.
Results
Of 512 randomized patients, 510 received erenumab 140 mg ( n = 254) or placebo ( n = 256) once monthly. Demographics and baseline characteristics were balanced between the two treatment arms. Erenumab 140 mg was superior to placebo in reducing duration of moderate or severe headache pain intensity over months 1, 2, and 3 (least squares mean [95% confidence interval {CI}] difference, −7.95 [−11.45, −4.46]; p < 0.001). Compared with placebo, erenumab significantly reduced migraine functional impact as assessed by the four domains of the Migraine Functional Impact Questionnaire, with a least squares mean (95% CI) difference of −7.36 (−10.80, −3.92) for physical functioning, −7.10 (−10.34, −3.87) for usual activities, −6.82 (−10.37, −3.27) for social functioning, and − 7.05 (−10.76, −3.34) for emotional functioning ( p < 0.001 for all domains). Significant reductions with erenumab compared with placebo were also observed in duration of at least moderate pain intensity in residual or break‐through migraine attacks (least squares mean [95% CI] difference, −1.07 [−1.92, −0.22]; p = 0.013) and peak migraine pain intensity (−0.48 [−0.85, −0.11]; p = 0.011). Incidence of grade 3 adverse events was 1.6% with erenumab and 1.2% with placebo; no grade 4 or fatal adverse events were reported in either treatment arm.
Conclusion
Findings from the EMBRACE study demonstrated that treatment with erenumab in patients with high‐frequency episodic migraine can provide positive therapeutic effects on ictal burden and pain, with residual migraine attacks tending to be shorter and less painful, with less overall impact.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Amgen Inc., Thousand Oaks, California, USA.
- Department of Frailty and Care ASST Spedali Civili, Headache Center, Brescia, Italy.
- Óbudai Egészségügyi Centrum, Budapest, Hungary.
- NZOZ Neuromed M i M Nastaj Spolka Partnerska, Lublin, Poland.
- Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
- IRCCS Fondazione C Mondino, Pavia, Italy.
ORCID-Profile: Gabriel Paiva da Silva Lima, David W Dodick
Förderung
- Amgen Inc.
- Amgen
Zitieren
APA
Paiva da Silva Lima, G., Rao, R., Szabó, G., Szklener, S., Tassorelli, C., Nastaj, M., Chou, D. E., Khodavirdi, A. C., Chehrenama, M., Zhu, Y., Bhatia, A. K., & Dodick, D. W. (2025). Comprehensive assessment of erenumab efficacy in participants with high‐frequency episodic migraine with at least one previously failed preventive treatment: The EMBRACE study. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.15071
Vancouver
Paiva da Silva Lima G, Rao R, Szabó G, Szklener S, Tassorelli C, Nastaj M, et al. Comprehensive assessment of erenumab efficacy in participants with high‐frequency episodic migraine with at least one previously failed preventive treatment: The EMBRACE study. Headache: The Journal of Head and Face Pain. 2025. doi:10.1111/head.15071
BibTeX
@article{PaivadaSilvaLima2025,
author = {Paiva da Silva Lima, Gabriel and Rao, Renata and Szabó, Gyöngyi and Szklener, Sebastian and Tassorelli, Cristina and Nastaj, Marcin and Chou, Denise E and Khodavirdi, Ani C and Chehrenama, Mahan and Zhu, Yineng and Bhatia, Ajay K and Dodick, David W},
title = {Comprehensive assessment of erenumab efficacy in participants with high‐frequency episodic migraine with at least one previously failed preventive treatment: The EMBRACE study},
journal = {Headache: The Journal of Head and Face Pain},
year = {2025},
doi = {10.1111/head.15071}
}
EUVIMED